Get the Stockscreener App
1,004.70
0.46%
-2.005
After Hours:
1003.12
-1.575
-0.16%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,004.70, with a volume of 1.71M.
It is down -0.46% in the last 24 hours and up +10.72% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,006.70
Open:
$1006.98
24h Volume:
1.71M
Relative Volume:
0.56
Market Cap:
$896.39B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
36.16
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+5.66%
1M Performance:
+10.72%
6M Performance:
-2.26%
1Y Performance:
+36.66%
1-Day Range:
$997.41
$1,014.38
1-Week Range:
$943.26
$1,022.82
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,005.21 | 897.72B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
226.74 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
210.37 | 372.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
148.08 | 285.77B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
181.58 | 286.84B | 60.48B | 10.40B | 8.05B | 3.3297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Editorial: Lilly earns kudos for 150 years of innovation, economic impact - Indianapolis Business Journal
My Top 3 Healthcare Stocks for May 2026 - The Motley Fool
Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal - RTTNews
Can Eli Lilly Benefit From Russell 1000 Healthcare Demand? - Kalkine Media
Analyst Raises Eli Lilly (LLY) Price Target by $52 Following Q1 Report - Insider Monkey
Eli Lilly & Co. stock (US5324571083): Q1 2026 earnings beat and guidance hike keep obesity boom stor - AD HOC NEWS
NVO Stock Pops Premarket: Novo Nordisk Unveils Fresh Wegovy Data That Could Narrow Eli Lilly’s Obesity Lead - Stocktwits
Byron Donalds trades in Chipotle, Eli Lilly, Intuit, and Marvell Technology stocks - Investing.com
Eli Lilly Growth Story Keeps S&P 500 Index Momentum Alive - Kalkine Media
Eli Lilly Growth Story Keeps S&P 500 Index In Focus - Kalkine Media
Jim Cramer Sees a ‘Bull Market’ for Eli Lilly Stock (LLY) - TipRanks
Is Eli Lilly Going To $1,100? - 24/7 Wall St.
Jim Cramer Believes “It Is a Bull Market for Eli Lilly” - Insider Monkey
Eli Lilly’s New Alopecia Drug Trial Moves Forward, Expanding Its Immunology Pipeline - TipRanks
Lilly’s Brenipatide IBS-C Trial Advances: What Investors Should Watch - TipRanks
BMO Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
Lilly announces $50M contribution to UNICEF USA for children’s health - Indianapolis Business Journal
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? - AOL.com
Lilly GLP-1 pill can keep weight off after stopping jabs, study finds - Chemist+Druggist
Eli Lilly & Co. stock (US5324571083): Q1 earnings beat with 55% revenue surge - AD HOC NEWS
Checkmate for Cancer: What Eli Lilly and Bayer Can Learn from Vidac Pharma - news.financial
Can Novo Nordisk close the gap to Eli Lilly? - Investors' Chronicle
Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vial - The Economic Times
Why is Eli Lilly stock rallying today? By Investing.com - Investing.com South Africa
Why is Eli Lilly stock rallying today? - Investing.com
Eli Lilly stock advances as Lormalzi (donanemab) launch in India boosts sentiment - Traders Union
Eli Lilly (LLY) Launches Alzheimer's Therapy Lormalzi in India - GuruFocus
HIMS Stock Crashes Overnight After Brutal Q1 — But An Investor Says Novo, Lilly Deals Could Make It ‘Netflix Of Healthcare’ - Stocktwits
Eli Lilly & Co. stock (US5324571083): Strong Q1 earnings beat and raised FY2026 guidance - AD HOC NEWS
Jim Cramer’s Take on 24 Stocks: Cisco, Eli Lilly, and Ford - Insider Monkey
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss - Benzinga
Encouraging Results for Eli Lilly's Orforglipron in Weight Loss Trials - GuruFocus
Lilly CEO David Ricks keeps eye on future while company celebrates history - Indianapolis Business Journal
BMO reiterates Eli Lilly stock Outperform on maintenance data - Investing.com
Parkland School Board tables vote on tax break for Eli Lilly - The Morning Call
Eli Lilly stock (US5324571083): Long-term weight loss trial success boosts obesity drug prospects - AD HOC NEWS
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - Moomoo
Eli Lilly on big upswing in research as Indy company marks 150 years - AOL.com
Eli Lilly Launches Alzheimer's Drug Lormalzi Priced At Rs 91,688 Per Vial In India - NDTV
Zacks Investment Ideas feature highlights Eli Lilly, Novo, JP Morgan, Coca-Cola, PepsiCO and Mondelez - Yahoo Finance Singapore
Eli Lilly launches Alzheimer’s drug in India at $957 per vial - Investing.com Nigeria
Eli Lilly launches Alzheimer’s drug in India at $957 per vial By Investing.com - Investing.com South Africa
Eli Lilly launches Alzheimer's drug Donanemab in India - Reuters
Alzheimer's a key part of Eli Lilly's India specialty medicine push, says company's country head Winselow - The Economic Times
Eli Lilly Clinical Trial Shows Its Obesity Drugs Can Cause Weight Loss And Help Maintain It - Stocktwits
Lilly, J&J CEOs top pharma’s highest paid list—again - BioSpace
Eli Lilly & Company CEO reflects on business’ 150-year history in Indianapolis - Fox 59
Eli Lilly (LLY) Reports Long-Term Weight Loss Success in Latest Trials - GuruFocus
AI and GLP-1 drugs: Eli Lilly & Co.’s CEO talks of focus beyond 150 years - WRTV
Lilly reports weight maintenance data for Foundayo, Zepbound - Investing.com
Lilly reports weight maintenance data for Foundayo, Zepbound By Investing.com - Investing.com Australia
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):